Поиск
Закладки
Озвучить текст Озвучить книгу
Изменить режим чтения
Изменить размер шрифта
Оглавление
Для озвучивания и цитирования книги перейдите в режим постраничного просмотра.
Остеопороз

Список литературы

  1. Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я., Торопцова Н.В., Алексеева Л.И., Бирюкова Е.В., Гребенникова Т.А., Дзеранова Л.К., Древаль А.В., Загородний Н.В., Ильин А.В., Крюкова И.В., Лесняк О.М, Мамедова Е.О., Никитинская О.А., Пигарова Е.А., Родионова С.С., Скрипникова И.А., Тарбаева Н.В., Фарба Л.Я., Цориев Т.Т., Чернова Т.О., Юренева С.В., Якушевская О.В., Дедов И.И.. Федеральные клинические рекомендации по диагностике, лечению и профилактике остеопороза. Проблемы Эндокринологии, 2017, Том 63, № 6, стр. 392-426
  2. Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL, Kleerekoper M, Lewiecki EM, Miller PD, Narula HS, Pessah-Pollack R, Tangpricha V,Wimalawansa SJ, Watts NB: American association of clinical endocrinologists and American college of endocrinology clinical practice guidelines for the diagnosis and treatment of postmenopausal osteoporosis -2016. Endocr Pract. 2016 Sep 2;22(Suppl 4):1-42.
  3. Kanis JA, Cooper C, Rizzoli R, Reginster JY; Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis (ESCEO) and the Committees of Scientific Advisors and National Societies of the International Osteoporosis Foundation (IOF).European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2019 Jan;30(1):3-44. doi: 10.1007/s00198-018- 4704-5
  4. Raman-Wilms L. Book Review: Guidelines for Preclinical Evaluation and Clinical Trials in Osteoporosis. Annals of Pharmacotherapy. 1999;33(12):1377-1378. doi:10.1177/106002809903301207.
  5. American Association of Orthopedic Surgeon Position Statement, 1159, December 2009
  6. Kanis JA, on behalf of the WHO Scientific Group. Assessment of osteoporosis at the primary health-care level. Technical Report. WHO Collaboraiting Centre, University of Sheffield, UK, 2008
  7. Consensus development conference: diagnosis, prophylaxis, and treatment of osteoporosis. Am J Med. 1993 Jun;94(6):646-50. DOI: 10.1016/0002-9343(93)90218-e
  8. Михайлов Е.Е., Беневоленская Л.И. Руководство по остеопорозу. М.: БИНОМ. Лаборатория знаний; 2003.
  9. Лесняк О.М., Ершова О.Б. Аудит состояния проблемы остеопороза в странах Восточной Европы и Центральной Азии 2010. Naturaprint; 2011
  10. Дедов И.И., Мельниченко Г.А., Белая Ж.Е., Рожинская Л.Я.: «Остеопороз – от редкого симптома эндокринных болезней до безмолвной эпидемии 20-21 века» Ж. Проблемы Эндокринологии, 2011, том 57, стр. 35-45
  11. Ершова О.Б., Белова К.Ю., Белов М.В., Ганерт О.А., Гладкова Е.Н., Ходырев В.Н., Лесняк О.М., Давтян В.Г., Пилюкова Р.И., Романова М.А., Синицина О.С Эпидемиология переломов проксимального отдела бедренной кости у городского населения Российской Федерации: результаты многоцентрового исследования. Форум остеопороза, 23-25 сентября, 2012; Санкт-Петербург. Материалы научно- практической конференции «Остеопороз – важнейшая мультидисциплинарная проблема здравоохранения XXI века»; 23–27.
  12. Меньшикова Л.В., Храмцова Н.А., Ершова О.Б. Ближайшие и отдаленные исходы переломов проксимального отдела бедра у лиц пожилого возраста и их медико- социальные последствия (по данным многоцентрового исследования). Остеопороз и остеопатии. 2002;1:8-11.
  13. Добровольская О.В., Торопцова Н.В., Лесняк О.М. Экономические аспекты осложненного остеопороза: стоимость лечения в течение первого года после перелома. Современная ревматология. 2016;. т. 10. № 3. с. 29-34.
  14. Бахтиярова С.А., Бортник С.Б., Лесняк О.М., Кузнецова Н.Л. Сравнительная оценка социальных последствий перелома проксимального отдела бедра и инфаркта миокарда у пациентов старшего возраста. Остеопороз и остеопатии. 2003; Приложение. Научная программа и тезисы Росс. Конгресса по остеопорозу, Москва, 20-22 октября 2003 г.- С.45
  15. Lesnyak O, Ershova O, Belova K et al. Epidemiology of fracture in the Russian Federation and the development of a FRAX model. Arch Osteoporos. 2012;7(1-2):67-73. doi:10.1007/s11657-012-0082-3.
  16. Cosman F, de Beur S, LeBoff M, de Beur SJ, Tanner B Clinician’s Guide to Prevention and Treatment of Osteoporosis. National Osteoporosis Foundation. 1150 17th St., NW, Suite 850, Washington, DC 20036, Release Date: April 1, 2014
  17. Shepstone L, Lenaghan E, Cooper C, et al. SCOOP Study Team. Screening in the community to reduce fractures in older women (SCOOP): a randomised controlled trial. Lancet. 2018 Feb 24;391(10122):741-747. doi: 10.1016/S0140-6736(17)32640-5.
  18. Turner DA, Khioe RFS, Shepstone L, et al. SCOOP Study Team. The Cost-Effectiveness of Screening in the Community to Reduce Osteoporotic Fractures in Older Women in the UK: Economic Evaluation of the SCOOP Study. J Bone Miner Res. 2018 May;33(5):845- 851. doi: 10.1002/jbmr.3381.
  19. Hippisley-Cox J, Coupland C (2009) Predicting risk of osteoporotic fracture in men and women in England and Wales: prospective derivation and validation of QFractures Scores. Br Med J 339: b4229
  20. Hoff M, Meyer HE, Skurtveit S et al (2017) Validation of FRAX and the impact of self- reported falls among elderly in a general population: the HUNT study, Norway. Osteoporos Int 28:2935–2944
  21. Fraser L-A, Langsetmo L, Berger C et al (2011) Fracture prediction and calibration of a Canadian FRAX® tool: a population-based report from CaMos. Osteoporos Int 22:829– 837
  22. Leslie WD, Lix LM, Johansson H et al (2010) Manitoba bone density program. Independent clinical validation of a Canadian FRAX((R)) tool: fracture prediction and model calibration. J Bone Miner Res 25:2350–2358
  23. Jiang X, Gruner M, Trémollieres F, Pluskiewicz W, Sornay-Rendu E, Adamczyk P, Schnatz PF. Diagnostic accuracy of FRAX in predicting the 10-year risk of osteoporotic fractures using the USA treatment thresholds: A systematic review and meta-analysis. Bone. 2017 Jun;99:20-25. doi: 10.1016/j.bone.2017.02.008.
  24. Marques A, Ferreira RJ, Santos E, Loza E, Carmona L, da Silva JA. The accuracy of osteoporotic fracture risk prediction tools: a systematic review and meta-analysis. Ann Rheum Dis. 2015 Nov;74(11):1958-67. doi: 10.1136/annrheumdis-2015-207907
  25. Kanis J, Johnell O, Oden A, Johansson H, McCloskey E. FRAX™ and the assessment of fracture probability in men and women from the UK. Osteoporosis International. 2008;19(4):385-397. doi:10.1007/s00198-007-0543-5
  26. Lindsay R, Silverman SL, Cooper C, Hanley DA, Barton I, Broy SB, et al. Risk of new vertebral fracture in the year following a fracture. JAMA. 2001;285:320-323
  27. Gehlbach S, Saag KG, Adachi JD, Hooven FH, Flahive J, Boonen S, et al. Previous fractures at multiple sites increase the risk for subsequent fractures: the Global Longitudinal Study of Osteoporosis in Women. J Bone Miner Res. 2012;27:645-653,
  28. Edwards BJ, Bunta AD, Simonelli C, Bolander M, Fitzpatrick LA. Prior fractures are common in patients with subsequent hip fractures. Clin Orthop Relat Res. 2007;461:226- 230
  29. Ross P. Pre-Existing Fractures and Bone Mass Predict Vertebral Fracture Incidence in Women. Annals of Internal Medicine. 1991;114(11):919. doi:10.7326/0003-4819-114-11- 919.
  30. Gallagher J, Genant H, Crans G, Vargas S, Krege J. Teriparatide Reduces the Fracture Risk Associated with Increasing Number and Severity of Osteoporotic Fractures. The Journal of Clinical Endocrinology & Metabolism. 2005;90(3):1583-1587. doi:10.1210/jc.2004- 0826
  31. Marcus R, Wang O, Satterwhite J, Mitlak B. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis. J Bone Miner Res. 2003;18(1):18-23. doi:10.1359/jbmr.2003.18.1.18.
  32. Kanis JA, Barton I, Johnell O. Risedronate decreases fracture risk in patients selected solely on the basis of prior vertebral fracture. Osteoporos Int 2005; 16: 475–82,
  33. Johnell O, Kanis JA, Black DM, et al. Association between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) study. J Bone Miner Res 2004; 19: 64–72,
  34. Kanis JA, Jonsson B, Oden A, McCloskey EV. A metaanalysis of the effect of strontium ranelate on the risk of vertebral and non-vertebral fracture in postmenopausal osteoporosis and the interaction with FRAX. Osteoporos Int 2011; 22: 2347–55.
  35. Kanis J.A., Johnell O., De Laet C., et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004; 35(2): 375-82.
  36. Klotzbuecher C.M., Ross P.D., Landsman P.B., et al. Patients with prior fractures have an increased risk of future fractures: a summary of the literature and statistical synthesis. J Bone Mineral Research 2000; 15(4): 721-39.
  37. Schousboe J, Ensrud K, Nyman J, Kane R, Melton L. Potential cost-effective use of spine radiographs to detect vertebral deformity and select osteopenic post-menopausal women for amino-bisphosphonate therapy. Osteoporosis International. 2005;16(12):1883-1893. doi:10.1007/s00198-005-1956-7
  38. Gallagher JC, Sai AJ. Bone: Is screening for secondary causes of osteoporosis worthwhile? Nat Rev Endocrinol. 2010;6:360-362
  39. Barzel US. Recommended testing in patients with low bone density. J Clin Endocrinol Metab. 2003;88:1404- 1405
  40. Tannenbaum C, Clark J, Schwartzman K, Wallenstein S, Lapinski R, Meier D, et al. Yield of laboratory testing to identify secondary contributors to osteoporosis in otherwise healthy women. J Clin Endocrinol Metab. 2002;87: 4431-4437
  41. Cerdá Gabaroi, D. et al. search for hidden secondary causes in postmenopausal women with osteoporosis. Menopause 17, 135–139 (2010)
  42. Deutschmann, H. A. et al. search for occult secondary osteoporosis: impact of identified possible risk factors on bone mineral density. J. Intern. Med. 252, 389–397 (2002)
  43. Priemel, M. et al. Bone mineralization defects and vitamin D deficiency: histomorphometric analysis of iliac crest bone biopsies and circulating 25-hydroxyvitamin D in 675 patients. J. Bone Miner. Res. 25, 305–312 (2009)
  44. Eastell R, Barton I, Hannon RA, Chines A, Garnero P, Delmas PD. Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate. J Bone Miner Res. 2003;18:1051-1056
  45. Hochberg M.C., Greenspan S., Wasnich R.D. et al. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J. Clin. Endocrinol. Metabol. 2002;87(4):1586–1592. doi: 10.1210/ jcem.87.4.8415
  46. Bone H.G., Hosking D., Devogelaer J.P. et al. Ten years’ experience with alendronate for osteoporosis in postmenopausal women. New Engl. J. Med. 2004;350(12):1189–99. doi: 10.1056/NEJMoa030897.
  47. Black D.M., Schwartz A.V., Ensrud K.E. et al. Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized tri- al. J. Am. Med. Association. 2006;296(24):2927–38. doi: 10.1001/ jama.296.24.2927
  48. Delmas PD, Eastell R, Garnero P, Seibel MJ, Stepan J (2000) The use of biochemical markers of bone turnover in osteoporosis. Committee of Scientific Advisors of the International Osteoporosis Foundation. Osteoporos Int 11(Suppl 6):S2–17
  49. Vasikaran S, Eastell R, Bruyère O, Foldes AJ, Garnero P, Griesmacher A, McClung M, Morris HA, Silverman S, Trenti T, Wahl DA, Cooper C, Kanis JA (2011) Markers of bone turnover for the prediction of fracture risk and monitoring of osteoporosis treatment: a need for international reference standards. Osteoporos Int 22:391–420
  50. Johansson H, Odén A, Kanis JA, McCloskey EV, Morris HA, Cooper C, Vasikaran S (2014) A meta-analysis of reference markers of bone turnover for prediction of fracture. Calcif Tissue Int 94:560–567
  51. Bauer DC, Black DM, Bouxsein ML, Lui LY, Cauley JA, de Papp AE, Grauer A, Khosla S, McCulloch CE, Eastell R; Foundation for the National Institutes of Health (FNIH) Bone Quality Project. Treatment-Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Anti-Resorptive Drugs: A Meta-Regression. J Bone Miner Res. 2018 Apr;33(4):634-642. doi: 10.1002/jbmr.3355. Epub 2018 Jan 10.
  52. Ravn P, Hosking D, Thompson D et al. Monitoring of Alendronate Treatment and Prediction of Effect on Bone Mass by Biochemical Markers in the Early Postmenopausal Intervention Cohort Study1. The Journal of Clinical Endocrinology & Metabolism. 1999;84(7):2363-2368. doi:10.1210/jcem.84.7.5847.
  53. Fink E, Cormier C, Steinmetz P, Kindermans C, Le Bouc Y, Souberbielle J. Differences in the Capacity of Several Biochemical Bone Markers to Assess High Bone Turnover in Early Menopause and Response to Alendronate Therapy. Osteoporosis International. 2000;11(4):295-303. doi:10.1007/pl00004183.
  54. Bauer D, Black D, Garnero P et al. Change in Bone Turnover and Hip, Non-Spine, and Vertebral Fracture in Alendronate-Treated Women: The Fracture Intervention Trial. J Bone Miner Res. 2004;19(8):1250-1258. doi:10.1359/jbmr.040512.
  55. Delmas P, Recker R, Chesnut C et al. Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study. Osteoporosis International. 2004;15(10). doi:10.1007/s00198-004-1602-9.
  56. Reginster J, Gieschke R. Clinical Utility of a Pharmacostatistical Model for Ibandronate in Postmenopausal Osteoporosis. CDM. 2006;7(7):827-836. doi:10.2174/138920006778520624.
  57. Krege J, Lane N, Harris J, Miller P. PINP as a biological response marker during teriparatide treatment for osteoporosis. Osteoporosis International. 2014;25(9):2159-2171. doi:10.1007/s00198-014-2646-0.
  58. Imaz I, Zegarra P, González-Enríquez J, Rubio B, Alcazar R, Amate J. Poor bisphosphonate adherence for treatment of osteoporosis increases fracture risk: systematic review and meta-analysis. Osteoporosis International. 2009;21(11):1943-1951. doi:10.1007/s00198-009-1134-4.
  59. Bergmann P, Body J, Boonen S et al. Evidence-based guidelines for the use of biochemical markers of bone turnover in the selection and monitoring of bisphosphonate treatment in osteoporosis: a consensus document of the Belgian Bone Club. International Journal of Clinical Practice. 2009;63(1):19-26. doi:10.1111/j.1742-1241.2008.01911.x.
  60. Burch J, Rice S, Yang H et al. Systematic review of the use of bone turnover markers for monitoring the response to osteoporosis treatment: the secondary prevention of fractures, and primary prevention of fractures in high-risk groups. Health Technology Assessment. 2014;18(11). doi:10.3310/hta18110.
  61. Dresner-Pollak R, Parker R, Poku M, Thompson J, Seibel M, Greenspan S. Biochemical Markers of Bone Turnover Reflect Femoral Bone Loss in Elderly Women. Calcified Tissue International. 1996;59(5):328-333. doi:10.1007/s002239900135.
  62. Ross PKnowlton W. Rapid Bone Loss Is Associated with Increased Levels of Biochemical Markers. J Bone Miner Res. 1998;13(2):297-302. doi:10.1359/jbmr.1998.13.2.297.
  63. Hansen MA, Overgaard K, Riis BJ et al. Role of peak bone mass and bone loss in postmenopausal osteoporosis: 12 year study. BMJ 1991; 303: 961–4
  64. Garnero P, Sornay-Rendu E, Duboeuf F, Delmas P. Markers of Bone Turnover Predict Postmenopausal Forearm Bone Loss Over 4 Years: The OFELY Study. J Bone Miner Res. 1999;14(9):1614-1621. doi:10.1359/jbmr.1999.14.9.1614.
  65. Tian, A., Ma, J., Feng, K. et al. Reference markers of bone turnover for prediction of fracture: a meta-analysis. J Orthop Surg Res 14, 68 (2019). https://doi.org/10.1186/s13018- 019-1100-6
  66. Schousboe J, Bauer D, Nyman J, Kane R, Melton L, Ensrud K. Potential for bone turnover markers to cost-effectively identify and select post-menopausal osteopenic women at high risk of fracture for bisphosphonate therapy. Osteoporosis International. 2006;18(2):201- 210. doi:10.1007/s00198-006-0218-7.
  67. Boonen S, Body J, Boutsen Y et al. Evidence-based guidelines for the treatment of postmenopausal osteoporosis: a consensus document of the Belgian Bone Club. Osteoporosis International. 2005;16(3):239-254. doi:10.1007/s00198-004-1812-1.
  68. McNabb B, Vittinghoff E, Schwartz A et al. BMD changes and predictors of increased bone loss in postmenopausal women after a 5-year course of alendronate. J Bone Miner Res. 2013;28(6):1319-1327. doi:10.1002/jbmr.1864.
  69. Bauer D, Schwartz A, Palermo L et al. Fracture Prediction After Discontinuation of 4 to 5 Years of Alendronate Therapy. JAMA Internal Medicine. 2014;174(7):1126.
  70. Cosman F, Cauley J, Eastell R et al. Reassessment of Fracture Risk in Women After 3 Years of Treatment With Zoledronic Acid: When is it Reasonable to Discontinue Treatment?. The Journal of Clinical Endocrinology & Metabolism. 2014;99(12):4546- 4554. doi:10.1210/jc.2014-1971.
  71. Bauer D, Garnero P, Hochberg M et al. Pretreatment Levels of Bone Turnover and the Antifracture Efficacy of Alendronate: The Fracture Intervention Trial. J Bone Miner Res. 2005;21(2):292-299. doi:10.1359/jbmr.051018.
  72. Seibel M, Naganathan V, Barton I, Grauer A. Relationship Between Pretreatment Bone Resorption and Vertebral Fracture Incidence in Postmenopausal Osteoporotic Women Treated With Risedronate. J Bone Miner Res. 2003;19(2):323-329. doi:10.1359/jbmr.0301231.
  73. Yamamoto T., Tsujimoto M., Hamaya E., Sowa H. Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis. J. Bone Miner. Metab. 2013;31:199–205. doi: 10.1007/s00774-012-0403-z
  74. Kanis J, Melton L, Christiansen C, Johnston C, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 2009;9(8):1137-1141. doi:10.1002/jbmr.5650090802.
  75. Nevitt MC, Ettinger B, Black DM, Stone K, Jamal SA, Ensrud K, Segal M, Genant HK, Cummings SR. The association of radiographically detected vertebral fractures with back pain and function: a prospective study. Ann Intern Med. 1998 May 15;128(10):793-800. doi: 10.7326/0003-4819-128-10-199805150-00001
  76. Yamamoto M, Yamaguchi T, Yamauchi M, Kaji H, Sugimoto T. Diabetic patients have an increased risk of vertebral fractures independent of BMD or diabetic complications. J Bone Miner Res. 2009 Apr;24(4):702-9. doi: 10.1359/jbmr.081207.
  77. Siminoski K, Jiang G, Adachi JD, Hanley DA, Cline G, Ioannidis G, Hodsman A, Josse RG, Kendler D, Olszynski WP, Ste Marie LG, Eastell R. Accuracy of height loss during prospective monitoring for detection of incident vertebral fractures. Osteoporos Int. 2005 Apr;16(4):403-10. doi: 10.1007/s00198-004-1709-z. Epub 2004 Aug 11
  78. T. P. van Staa, H. G. M. Leufkens, L. Abenhaim, B. Zhang, C. Cooper, Oral corticosteroids and fracture risk: relationship to daily and cumulative doses, Rheumatology, Volume 39, Issue 12, December 2000, Pages 1383–1389, https://doi.org/10.1093/rheumatology/39.12.1383
  79. Dede AD, Tournis S, Dontas I, Trovas G. Type 2 diabetes mellitus and fracture risk. Metabolism. 2014 Dec;63(12):1480-90. doi: 10.1016/j.metabol.2014.09.002.
  80. Xu W, Perera S, Medich D, Fiorito G, Wagner J, Berger LK, Greenspan SL. Height loss, vertebral fractures, and the misclassification of osteoporosis. Bone. 2011 Feb;48(2):307- 11. doi: 10.1016/j.bone.2010.09.027. Epub 2010 Sep 24
  81. Kamimura, M., Nakamura, Y., Sugino, N. et al. Associations of self-reported height loss and kyphosis with vertebral fractures in Japanese women 60 years and older: a cross- sectional survey. Sci Rep 6, 29199 (2016). https://doi.org/10.1038/srep29199
  82. Mikula, A.L., Hetzel, S.J., Binkley, N. et al. Validity of height loss as a predictor for prevalent vertebral fractures, low bone mineral density, and vitamin D deficiency. Osteoporos Int 28, 1659–1665 (2017). https://doi.org/10.1007/s00198-017-3937-z
  83. Genant H, Wu C, van Kuijk C, Nevitt M. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res. 1993;8(9):1137-1148. doi:10.1002/jbmr.5650080915.
  84. Genant H.K., Jergas M. Assessment of prevalent and incident vertebral fractures in osteoporosis research. Osteoporosis Int. 2003;14(3):43–55.
  85. Kazawa N. T2WI MRI and MRI-MDCT correlations of the osteoporotic vertebral compressive fractures. European Journal of Radiology. 2012;81(7):1630-1636. doi:10.1016/j.ejrad.2011.04.052.
  86. Baum T, Karampinos D, Liebl H, Rummeny E, Waldt S, Bauer J. High-Resolution Bone Imaging for Osteoporosis Diagnostics and Therapy Monitoring Using Clinical MDCT and MRI. CMC. 2013;20(38):4844-4852. doi:10.2174/09298673113206660279.
  87. Lenchik L, Rogers L, Delmas P, Genant H. Diagnosis of Osteoporotic Vertebral Fractures: Importance of Recognition and Description by Radiologists. American Journal of Roentgenology. 2004;183(4):949-958. doi:10.2214/ajr.183.4.1830949.
  88. Grigoryan M, Guermazi A, Roemer F, Delmas P, Genant H. Recognizing and reporting osteoporotic vertebral fractures. European Spine Journal. 2003;12(0):S104-S112. doi:10.1007/s00586-003-0613-0.
  89. Papadakis A, Karantanas A, Papadokostakis G, Petinellis E, Damilakis J. Can abdominal multi-detector CT diagnose spinal osteoporosis?. Eur Radiol. 2008;19(1):172-176. doi:10.1007/s00330-008-1099-2.
  90. Papadakis A, Karantanas A, Papadokostakis G, Damilakis J. Assessment of the morpho- densitometric parameters of the lumbar pedicles in osteoporotic and control women undergoing routine abdominal MDCT examinations. J Bone Miner Metab. 2010;29(3):352-358. doi:10.1007/s00774-010-0227-7.
  91. Baum T, Grande Garcia E, Burgkart R et al. Osteoporosis imaging: effects of bone preservation on MDCT-based trabecular bone microstructure parameters and finite element models. BMC Medical Imaging. 2015;15(1). doi:10.1186/s12880-015-0066-z.
  92. Damilakis J, Adams J, Guglielmi G, Link T. Radiation exposure in X-ray-based imaging techniques used in osteoporosis. Eur Radiol. 2010;20(11):2707-2714. doi:10.1007/s00330- 010-1845-0.
  93. Kanis JA, Harvey NC, Cooper C et al. A systematic review of intervention thresholds based on FRAX: A report prepared for the National Osteoporosis Guideline Group and the International Osteoporosis Foundation. Arch Osteoporos. 2016 Dec;11(1):25. doi: 10.1007/s11657-016-0278-z
  94. Merlijn T, Swart KMA, van der Horst HE, Netelenbos JC, Elders PJM (2020) Fracture prevention by screening for high fracture risk: a systematic review and meta-analysis. Osteoporos Int 31:251–257
  95. Rubin KH, Rothmann MJ, Holmberg T, Høiberg M, Möller S, Barkmann R, Glüer CC, Hermann AP, Bech M, Gram J, Brixen K (2018) Effectiveness of a two-step population- based osteoporosis screening program using FRAX: the randomized Risk-stratified Osteoporosis Strategy Evaluation (ROSE) study. Osteoporos Int 29: 567–578
  96. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Oden A; National Osteoporosis Guideline Group. Case finding for the management of osteoporosis with FRAX--assessment and intervention thresholds for the UK. Osteoporos Int. 2008 Oct;19(10):1395-408. doi: 10.1007/s00198-008-0712-1
  97. Kanis J, Johnell O, De Laet C, Jonsson B, Oden A, Ogelsby A. International Variations in Hip Fracture Probabilities: Implications for Risk Assessment. J Bone Miner Res. 2002;17(7):1237-1244. doi:10.1359/jbmr.2002.17.7.1237.
  98. De Laet C, Van Hout B, Burger H, Weel A, Hofman A, Pols H. Hip Fracture Prediction in Elderly Men and Women: Validation in the Rotterdam Study. J Bone Miner Res. 2009;13(10):1587-1593. doi:10.1359/jbmr.1998.13.10.1587.
  99. Kanis JA, Delmas P, Burckhardt P, Cooper C, Torgerson D. Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease. Osteoporos Int. 1997;7(4):390-406. DOI: 10.1007/bf01623782
  100. Kanis JA, McCloskey EV, Johansson H, Cooper C, Rizzoli R, Reginster J-Y, on behalf of the Scientific Advisory Board of the European Society for Clinical and Economic Aspects of Osteoporosis and Osteoarthritis (ESCEO) and the Committee of Scientific Advisors of the International Osteoporosis Foundation (IOF). European guidance for the diagnosis and management of osteoporosis in postmenopausal women. Osteoporos Int. 2013 Jan;24(1):23-57. doi: 10.1007/s00198-012-2074-y.
  101. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgström F, Cooper C, Diez Perez A, Eastell R, Hofbauer L, Kanis JA, Langdahl BL, Lesnyak O, Lorenc R, McCloskey E, Messina OD, Napoli N, Obermayer-Pietsch B, Ralston SH, Sambrook PN, Silverman S, Sosa M, Stepan J, Suppan G, Wahl DA, Compston JE for the Joint IOF-ECTS GIO Guidelines Working Group. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012 Sep;23(9):2257-76. doi: 10.1007/s00198-012-1958-1
  102. Алексеева ЛИ, Баранова ИА, Белова КЮ, Ершова ОБ, Зазерская ИЕ, Зоткин ЕГ, Лесняк ОМ, Никитинская ОА, Рожинская ЛЯ, Скрипникова ИА, Смирнов АВ, Щеплягина ЛА.: Клинические рекомендации по профилактике и ведению больных с остеопорозом. Литера;2012:23.
  103. Никитинская О.А., Торопцова Н.В. Оценка риска переломов с использованием модели FRAX® (ретроспективное десятилетнее исследование) Альманах клинической медицины. 2014;43:50-55.
  104. National Osteoporosis Foundation (NOF) and International Society for Clinical Densitometry (ISCD). Recommendations to DXA Manufacturers for FRAX® Implementation. Available http://www.nof.org/files/nof/public/content/resource/862/files/392.pdf. Accessed January 28, 2013
  105. Kanis JA, Johansson H, Odén A, McCloskey EV. Guidance for the adjustment of FRAX according to the dose of glucocorticoids. Osteoporos Int 2011: 22:809–816
  106. Kanis JA, Johansson H, Oden A et al. A meta-analysis of prior corticosteroid use and fracture risk. J Bone Miner Res. 2004 Jun;19(6):893-9. DOI: 10.1359/JBMR.040134
  107. Van Staa TP, Leufkens HGM, Cooper C. The epidemiology of corticosteroid- induced osteoporosis: a meta-analysis. Osteoporos Int. 2002 Oct;13(10):777-87.
  108. Ferrari SL, Abrahamsen B, Napoli N, et al; Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge.Osteoporos Int. 2018 Dec;29(12):2585-2596. doi: 10.1007/s00198-018-4650-2
  109. Leslie WD, Johansson H, McCloskey EV, Harvey NC, Kanis JA, Hans D. Comparison of Methods for Improving Fracture Risk Assessment in Diabetes: The Manitoba BMD Registry. J Bone Miner Res. 2018 Nov;33(11):1923-1930. doi: 10.1002/jbmr.3538
  110. Baleanu F, Bergmann P, Hambye AS, Dekelver C, Iconaru L, Cappelle SI, Moreau M, Paesmans M, Karmali R, Body JJ. Assessment of bone quality with trabecular bone score in type 2 diabetes mellitus: A study from the FRISBEE cohort. Int J Clin Pract. 2019 Mar 26:e13347. doi: 10.1111/ijcp.13347
  111. Johansson H, Odén A, Johnell O, Jonsson B, de Laet C, Oglesby A, McCloskey EV, Kayan K, Jalava T, Kanis JA (2004) Optimization of BMD measurements to identify high risk groups for treatment—a test analysis. J Bone Miner Res 19:906–913
  112. Tosteson AN, Melton LJ, 3rd, Dawson-Hughes B, Baim S, Favus MJ, Khosla S, Lindsay RL (2008) Cost-effective osteoporosis treatment thresholds: the United States perspective. Osteoporos Int 19:437–447
  113. Leslie WD, Morin S, Lix LM, Johansson H, Odén A, McCloskey E, Kanis JA (2012) Fracture risk assessment without bone density measurement in routine clinical practice. Osteoporos Int 23:75–85
  114. Leslie WD, Majumdar SR, Lix LM, Johansson H, Odén A, McCloskey E, Kanis JA (2012) High fracture probability with FRAX usually indicates densitometric osteoporosis: implications for clinical practice. Osteoporos Int 23:391–397
  115. Kanis JA, Odén A, Johnell O, et al. The use of clinical risk factors enhances the performance of BMD in the prediction of hip and osteoporotic fractures in men and women. Osteoporos Int (2007) 18:1033–1046.
  116. Kyriakos G, Vidal-Casariego A, Fernandez-Martinez MN et al. Impact of the NOGG and NOF guidelines on the indication of bone mineral density in routine clinical practice. J Clin Densitom. 2015 Oct-Dec;18(4):533-8. doi: 10.1016/j.jocd.2015.08.001.
  117. Kanis JA, McCloskey EV, Johansson H, Strom O, Borgstrom F, Odén A. Case finding for the management of osteoporosis with FRAX—assessment and intervention thresholds for the UK. Osteoporos Int. 2008;19:1395–1408.
  118. Johansson H, Kanis JA, Oden A, Johnell O, McCloskey E BMD, clinical risk factors and their combination for hip fracture prevention. Osteoporos Int (2009) 20: 1675- 1682.
  119. Johansson H, Kanis JA, Oden A, Compston J, McCloskey E A comparison of case- finding strategies in the UK for the management of hip fractures. Osteoporos Int (2012) 23:907–915.
  120. Kanis JA, Adams J, Borgström F et al. The cost-effectiveness of alendronate in the management of osteoporosis. Bone (2008) 42: 4-15.
  121. Cummings SR, Karpf DB, Harris F, Genant HK, Ensrud K, LaCroix AZ, Black DM. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281–289.
  122. Chen P, Miller PD, Delmas PD, Misurski DA, Krege JH. Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis. J Bone Miner Res. 2006;21:1785–1790.
  123. Management of postmenopausal osteoporosis: position statement of The North American Menopause Society. Menopause. 2002:84-101. doi:10.1097/00042192- 200203000-00003.
  124. ISCD positions. Journal of Clinical Densitometry. 2004;7(1).
  125. Official Positions of the International Society for Clinical Densitometry. Copyright ISCD, October 2007.
  126. Shepherd JA, Blake GM . T-scores and Z-scores. J Clin Densitom. 2007 Oct- Dec;10(4):349-50. DOI: 10.1016/j.jocd.2007.08.006
  127. Watts NB, Leslie WD, Foldes AJ, Miller PD. International Society for Clinical Densitometry Position Development Conference: Task Force on Normative Databases. J Clin Densitom. 2013 Oct-Dec;16(4):472-81. doi: 10.1016/j.jocd.2013.08.001.
  128. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. World Health Organization, Geneva. World Health Organ Tech Rep Ser. 1994;843:1-129.
  129. Kelly TL. Bone mineral density reference databases for American men and women. J Bone Miner Res 1990, 5(Suppl 2):S249.
  130. Hanson J. Standardization of femur BMD. J Bone Miner Res 1997, 12:1316e1317.
  131. Kanis JA, McCloskey EV, Johansson H, Oden A, Melton LJ 3rd, Khaltaev N. A reference standard for the description of osteoporosis. Bone. 2008 Mar;42(3):467-75. doi: 10.1016/j.bone.2007.11.001.
  132. Nelson HD, Haney EM, Chou R, Dana T, Fu R, Bougatsos C. Screening for Osteoporosis: Systematic Review to Update the 2002 US Preventive Services Task Force Recommendation. Rockville (MD): Agency for Healthcare Research and Quality (US); 2010 Jul. Report No.: 10-05145-EF-1.
  133. Melton LJ. Chrischilles EA, Cooper C, Lane AW, Riggs BL. How many women have osteoporosis. J Bone Miner Res 1993:7: 1005-1010.
  134. Bonnick S. Bone Densitometry in Clinical Practice. Humana Press Inc. 2004:411.
  135. McCloskey EV, Odén A, Harvey NC, et al. A Meta-Analysis of Trabecular Bone Score in Fracture Risk Prediction and its Relationship to FRAX. J Bone Miner Res. 2016 May;31(5):940-8. doi: 10.1002/jbmr.2734.
  136. Bousson V, Bergot C, Sutter B, Levitz P, Cortet B. Trabecular bone score (TBS): available knowledge, clinical relevance, and future prospects. Osteoporosis International. 2011;23(5):1489-1501. doi:10.1007/s00198-011-1824-6.
  137. International Society for Clinical Densitometry. 2013 Official Positions - Adult. http://www.iscd.org/ official-positions/2013-iscd-official-positions-adult. Ссылка активна на 12.05.2019.
  138. Black DM, Cummings SR, Karpf DB et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet. 1996; 348:1535–1541.
  139. Cummings SR, Black DM, Thompson DE et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998; 280:2077–2082. doi:10.1001/jama.280.24.2077
  140. Orwoll E, Ettinger M, Weiss S, Miller P, Kendler D, Graham J, Adami S, Weber K, Lorenc R, Pietschmann P, Vandormael K, Lombardi A. Alendronate for the treatment of osteoporosis in men. N Engl J Med. 2000 Aug 31;343(9):604-10. DOI: 10.1056/NEJM200008313430902
  141. Saag K, Emkey R, Schnitzer T et al. Alendronate for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Obstetrical & Gynecological Survey. 1999;54(1):39-40. doi:10.1097/00006254-199901000-00021
  142. McClung MR, Geusens P , Miller PD , et al.Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.N Engl J Med. 2001; 344: 333-340
  143. Boonen S, Orwoll E, Wenderoth D, Stoner K, Eusebio R, Delmas P. Once-Weekly Risedronate in Men With Osteoporosis: Results of a 2-Year, Placebo-Controlled, Double- Blind, Multicenter Study. Journal of Bone and Mineral Research. 2009;24(4):719-725. doi:10.1359/jbmr.081214
  144. Eastell R, Devogelaer J, Peel N et al. Prevention of Bone Loss with Risedronate in Glucocorticoid-Treated Rheumatoid Arthritis Patients. Osteoporosis International. 2000;11(4):331-337. doi:10.1007/s001980070122
  145. Chesnut CH 3rd, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD; Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE). Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res. 2004 Aug;19(8):1241-9. Epub 2004 Mar 29.
  146. Miller PD, McClung MR, Macovei L, Stakkestad JA, Luckey M, Bonvoisin B, Reginster JY, Recker RR, Hughes C, Lewiecki EM, Felsenberg D, Delmas PD, Kendler DL, Bolognese MA, Mairon N, Cooper C. Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study J Bone Miner Res. 2005 Aug;20(8):1315-22. Epub 2005 Mar 14.
  147. Recker RR, Ste-Marie LG, Langdahl B, Czerwinski E, Bonvoisin B, Masanauskaite D, Rowell L, Felsenberg D. Effects of intermittent intravenous ibandronate injections on bone quality and micro-architecture in women with postmenopausal osteoporosis: the DIVA study. Bone. 2010 Mar;46(3):660-5. doi: 10.1016/j.bone.2009.11.004. Epub 2009 Nov 10.
  148. Harris S, Blumentals W, Miller P. Ibandronate and the risk of non-vertebral and clinical fractures in women with postmenopausal osteoporosis: results of a meta-analysis of phase III studies. Current Medical Research and Opinion. 2007;24(1):237-245. doi:10.1185/030079908x253717
  149. Black D, Delmas P, Eastell R et al. Once-Yearly Zoledronic Acid for Treatment of Postmenopausal Osteoporosis. N Engl J Med. 2007 May 3;356(18):1809-22 DOI: 10.1056/NEJMoa067312
  150. Boonen S, Reginster J, Kaufman J et al. Fracture Risk and Zoledronic Acid Therapy in Men with Osteoporosis. New England Journal of Medicine. 2012;367(18):1714-1723
  151. Reid DM, Devogelaer JP, Saag K, Roux C, Lau CS, Reginster JY, Papanastasiou P, Ferreira A, Hartl F, Fashola T, Mesenbrink P, Sambrook PN; HORIZON investigators. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2009 Apr 11;373(9671):1253-63. doi: 10.1016/S0140- 6736(09)60250-6
  152. Kenneth W. Lyles, Cathleen S. Colón-Emeric, M.H.Sc., Jay S. Magaziner, et al for the HORIZON Recurrent Fracture Trial* Zoledronic Acid and Clinical Fractures and Mortality after Hip Fracture. N Engl J Med. 2007;357:1799-1809
  153. McClung M, Miller P, Recknor C, Mesenbrink P, Bucci-Rechtweg C, Benhamou C. Zoledronic Acid for the Prevention of Bone Loss in Postmenopausal Women With Low Bone Mass. Obstetrics & Gynecology. 2009;114(5):999-1007. doi:10.1097/aog.0b013e3181bdce0a
  154. Reid IR, Horne AM, Mihov B, Stewart A, Garratt E, Wong S, Wiessing KR, Bolland MJ, Bastin S, Gamble GD. Fracture Prevention with Zoledronate in Older Women with Osteopenia. N Engl J Med. 2018 Dec 20;379(25):2407-2416. doi: 10.1056/NEJMoa1808082
  155. Cummings S, Martin J, McClung M et al. Denosumab for Prevention of Fractures in Postmenopausal Women With Osteoporosis. N Engl J Med. 2009 Aug 20;361(8):756- 65. doi: 10.1056/NEJMoa0809493. Epub 2009 Aug 11
  156. Langdahl B, Teglbjærg C, Ho P et al. A 24-Month Study Evaluating the Efficacy and Safety of Denosumab for the Treatment of Men With Low Bone Mineral Density: Results From the ADAMO Trial. The Journal of Clinical Endocrinology & Metabolism. 2015;100(4):1335-1342. doi:10.1210/jc.2014-4079
  157. Orwoll E, Teglbjærg C, Langdahl B et al. A Randomized, Placebo-Controlled Study of the Effects of Denosumab for the Treatment of Men with Low Bone Mineral Density. The Journal of Clinical Endocrinology & Metabolism. 2012;97(9):3161-3169. doi:10.1210/jc.2012-1569
  158. Saag KG, Pannacciulli N, Geusens P, Adachi JD, Messina OD, Morales-Torres J, Emkey R, Butler PW, Yin X, Lems WF. Denosumab vs risedronate in glucocorticoid- induced osteoporosis: final results of a 24-month randomized, double-blind, double- dummy trial. Arthritis Rheumatol. 2019 Feb 28. doi: 10.1002/art.40874
  159. Gnant M, Pfeiler G, Dubsky P et al. Adjuvant denosumab in breast cancer (ABCSG- 18): a multicentre, randomised, double-blind, placebo-controlled trial. The Lancet. 2015;386(9992):433-443. doi:10.1016/s0140-6736(15)60995-3
  160. Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C; DenosumabHALT Prostate Cancer Study Group. Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med. 2009 Aug 20;361(8):745-55. doi: 10.1056/NEJMoa0809003. Epub 2009 Aug 11.
  161. Amiche MA, Albaum JM, Tadrous M, et al. Efficacy of osteoporosis pharmacotherapies in preventing fracture among oral glucocorticoid users: a network. Osteoporos Int. 2016 Jun;27(6):1989-98. doi: 10.1007/s00198-015-3476-4.
  162. Benlidayi IC. Denosumab in the treatment of glucocorticoid-induced osteoporosis. Rheumatol Int. 2018 Nov;38(11):1975-1984. doi: 10.1007/s00296-018-4106-1.
  163. Yamaguchi Y, Morita T, Kumanogoh A. The therapeutic efficacy of denosumab for the loss of bone mineral density in glucocorticoid-induced osteoporosis: a meta- analysis. Rheumatol Adv Pract. 2020 Mar 13;4(1):rkaa008. doi: 10.1093/rap/rkaa008.
  164. Yanbeiy ZA, Hansen KE. Denosumab in the treatment of glucocorticoid-induced osteoporosis: a systematic review and meta-analysis. Drug Des Devel Ther. 2019 Aug 14;13:2843-2852. doi: 10.2147/DDDT.S148654.
  165. Miller P, Bolognese M, Lewiecki E et al. Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: A randomized blinded phase 2 clinical trial. Bone. 2008;43(2):222-229. doi:10.1016/j.bone.2008.04.007
  166. Mandema JW1, Zheng J, Libanati C, Perez Ruixo JJ. Time course of bone mineral density changes with denosumab compared with other drugs in postmenopausal osteoporosis: a dose-response-based meta-analysis.J Clin Endocrinol Metab. 2014 Oct;99(10):3746-55. doi: 10.1210/jc .2013-3795. Epub 2014 Jun 10
  167. Brown J, Prince R, Deal C et al. Comparison of the Effect of Denosumab and Alendronate on BMD and Biochemical Markers of Bone Turnover in Postmenopausal Women With Low Bone Mass: A Randomized, Blinded, Phase 3 Trial*. Journal of Bone and Mineral Research. 2009;24(1):153-161. doi:10.1359/jbmr.0809010
  168. Choi NK, Solomon DH, Tsacogianis TN, Landon JE, Song HJ, Kim SC.Comparative Safety and Effectiveness of Denosumab Versus Zoledronic Acid in Patients With Osteoporosis: A Cohort Study. J Bone Miner Res. 2016 Oct 13. doi: 10.1002/jbmr.3019.
  169. Kendler D, Roux C, Benhamou C et al. Effects of denosumab on bone mineral density and bone turnover in postmenopausal women transitioning from alendronate therapy. J Bone Miner Res. 2009;25(1):72-81. doi:10.1359/jbmr.090716.
  170. Tsai J, Uihlein A, Burnett-Bowie S et al. Comparative Effects of Teriparatide, Denosumab, and Combination Therapy on Peripheral Compartmental Bone Density, Microarchitecture, and Estimated Strength: the DATA-HRpQCT Study. J Bone Miner Res. 2014;30(1):39-45. doi:10.1002/jbmr.2315.
  171. Broadwell A, Chines A, Ebeling PR, Franek E, Huang S, Smith S, Kendler D, Messina O, Miller PD. Denosumab Safety and Efficacy Among Participants in the FREEDOM Extension Study With Mild to Moderate Chronic Kidney Disease. J Clin Endocrinol Metab. 2021 Jan 23;106(2):397-409. doi: 10.1210/clinem/dgaa851. PMID: 33211870; PMCID: PMC7823314.
  172. Meier C, Uebelhart B, Aubry-Rozier B, Birkhäuser M, Bischoff-Ferrari HA, Frey D, Kressig RW, Lamy O, Lippuner K, Stute P, Suhm N, Ferrari S. Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the SVGO/ASCO. Swiss Med Wkly. 2017 Aug 16;147:w14484. doi: 10.4414/smw.2017.14484.
  173. Miller PD, Pannacciulli N, Brown JP, Czerwinski E, Nedergaard BS, Bolognese MA, Malouf J, Bone HG, Reginster JY, Singer A, Wang C, Wagman RB, Cummings SR. Denosumab or Zoledronic Acid in Postmenopausal Women With Osteoporosis Previously Treated With Oral Bisphosphonates. J Clin Endocrinol Metab. 2016 Aug;101(8):3163-70. doi: 10.1210/jc.2016-1801.
  174. McClung M. Inhibition of RANKL as a treatment for osteoporosis: Preclinical and early clinical studies. Current Osteoporosis Reports. 2006;4(1):28-33. doi:10.1007/s11914-006-0012-7
  175. Белая Ж.Е., Рожинская Л.Я. Новые направления в терапии остеопороза – применение моноклональных человеческих антител к RANKL (Деносумаб). Остеопороз и Остеопатии. 2011;2:19-22
  176. Neer R, Arnaud C, Zanchetta J et al. Effect of Parathyroid Hormone (1-34) on Fractures and Bone Mineral Density in Postmenopausal Women With Osteoporosis. N Engl J Med. 2001 May 10;344(19):1434-41 DOI:10.1056/NEJM200105103441904
  177. Orwoll E, Scheele W, Paul S et al. The Effect of Teriparatide [Human Parathyroid Hormone (1-34)] Therapy on Bone Density in Men With Osteoporosis. J Bone Miner Res. 2003;18(1):9-17. doi:10.1359/jbmr.2003.18.1.9.
  178. Saag K, Shane E, Boonen S et al. Teriparatide or Alendronate in Glucocorticoid- Induced Osteoporosis. N Engl J Med. 2007 Nov 15;357(20):2028-39 DOI:10.1056/NEJMoa071408
  179. Saag K, Zanchetta J, Devogelaer J et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: Thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis & Rheumatism. 2009;60(11):3346- 3355. doi:10.1002/art.24879
  180. Liu CL, Lee HC, Chen CC, Cho DY. Head-to-head comparisons of bisphosphonates and teriparatide in osteoporosis: a meta-analysis. Clin Invest Med. 2017;40(3):E146-E157. doi: 10.25011/cim.v40i3.28394.
  181. Wang YK, Qin SQ, Ma T, Song W, Jiang RQ, Guo JB, Li K, Zhang YM. Effects of teriparatide versus alendronate for treatment of postmenopausal osteoporosis: A meta- analysis of randomized controlled trials. Medicine (Baltimore). 2017;96(21):e6970. doi: 10.1097/MD.0000000000006970.
  182. Kendler DL, Marin F, Zerbini CAF, et al. Effects of teriparatide and risedronate on new fractures in post-menopausal women with severe osteoporosis (VERO): a multicentre, double-blind, double-dummy, randomised controlled trial. Lancet. 2018 Jan 20;391(10117):230-240. doi: 10.1016/S0140-6736(17)32137-2
  183. Body J, Gaich G, Scheele W et al. A Randomized Double-Blind Trial to Compare the Efficacy of Teriparatide [Recombinant Human Parathyroid Hormone (1–34)] with Alendronate in Postmenopausal Women with Osteoporosis. The Journal of Clinical Endocrinology & Metabolism. 2002;87(10):4528-4535. doi:10.1210/jc.2002-020334.
  184. Hadji P, Zanchetta J, Russo L et al. Effect of teriparatide compared with risedronate on back pain and incident vertebral fractures in postmenopausal women with osteoporotic vertebral fractures. Bone. 2011;48:S82-S83. doi:10.1016/j.bone.2011.03.108.
  185. Miller PD, Shergy WJ, Body J, Chen P, Rohe ME, Krege JH.: Longterm reduction of back pain risk in women with osteoporosis treated with teriparatide compared with alendronate
  186. European Medicines Agency Press Office. EMEA recommends changes in the product Information for Protelos/Osseor due to the risk of severe hypersensitivity reactions. EMEA/417458/2007
  187. European Medicines Agency: Recommendation to restrict the use of Protelos/Osseor (strontium ranelate) 25 April 2013 EMA/258269/2013
  188. European Medicines Agency: Protelos/Osseor (strontium ranelate) to remain available but with futher restrictions 15 April 2014 EMA 235924/2014. J Rheumatology. 2005;32:1556-1562.
  189. O’Donnel S, Cranney A, Wells GA, Adachi J, Reginster JY (2008) Strontium ranelate for preventing and treating osteoporosis. The Cochrane Library, Issue 4
  190. Adler R, El-Hajj Fuleihan G, Bauer D et al. Managing Osteoporosis in Patients on Long-Term Bisphosphonate Treatment: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2016;31(1):16-35. doi:10.1002/jbmr.2708
  191. Black DM, Boonen S, Cauley JA, Cummings SR, Lippuner K, Leung PC, Martinez RLM, Ruzycky ME, Eastell R (2012a) Erratum: The effect of 3 versus 6 years of Zoledronic acid treatment of osteoporosis: A randomized extension to the horizon-pivotal fracture trial (PFT). J Bone Miner Res 27(12):2612,
  192. Black DM, Reid IR, Cauley JA, Cosman F, Leung PC, Lakatos P, Lippuner K, Cummings SR, Hue TF, Mukhopadhyay A, Tan M, Aftring RP, Eastell R (2015) The effect of 6 versus 9 years of zoledronic acid treatment in osteoporosis: A randomized second extension to the HORIZON-pivotal fracture trial (PFT). J Bone Miner Res 30(5): 934-944
  193. Dennison EM, Cooper C, Kanis JA, Bruyère O, Silverman S, McCloskey E, Abrahamsen B, Prieto-Alhambra D, Ferrari S; IOF Epidemiology/Quality of Life Working Group. Fracture risk following intermission of osteoporosis therapy. Osteoporos Int. 2019 Jun 7. doi: 10.1007/s00198-019-05002-w.
  194. Bone HG, Wagman RB, Brandi ML, Brown JP, Chapurlat R, Cummings SR, Czerwiński E, Fahrleitner-Pammer A, Kendler DL, Lippuner K, Reginster JY, Roux C, Malouf J, Bradley MN, Daizadeh NS, Wang A, Dakin P, Pannacciulli N, Dempster DW, Papapoulos S. 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open- label extension. Lancet Diabetes Endocrinol 2017 5(7):513-23
  195. Bone HG, Bolognese MA, Yuenn CK, Kendler DL, Miller PD, Yang YC, Grazette L, Martin JS, Gallagher JC (2011) Effects of denosumab treatment and discontinuation on bone mineral density and bone turnover markers in postmenopausal women with low bone mass. J Clin Endocrinol Metab 96(4):972- 980
  196. Bone HG, Chapurlat R, Brandi ML, et al. (2013) The effect of three or six years of denosumab exposure in women with postmenopausal osteoporosis: Results from the FREEDOM extension. J Clin Endocrinol Metab 98(11):4483-4492
  197. Anagnostis P, Paschou SA, Mintziori G, Ceausu I, Depypere H, Lambrinoudaki I, Mueck A, Perez-Lopez FR, Rees M, Senturk LM, Simoncini T, Stevenson JC, Stute P, Tremollieres FA, Goulis DG Drug holidays from bisphosphonates and denosumab in postmenopausal osteoporosis: EMAS position statement. Maturitas, 2017, 101; 23030
  198. Белая Ж.Е., Bilezikian J.P., Ершова О.Б., и др. Возможности длительной терапии постменопаузального остеопороза: обзор результатов клинических исследований деносумаба и резолюция совета экспертов российской ассоциации по остеопорозу (РАОП). Ж. Остеопороз и Остеопатии, 2018, Том 21, стр. 4-9
  199. Brown J, Roux C, Törring O et al. Discontinuation of denosumab and associated fracture incidence: Analysis from the Fracture Reduction Evaluation of Denosumab in Osteoporosis Every 6 Months (FREEDOM) Trial. J Bone Miner Res. 2013;28(4):746-752. doi:10.1002/jbmr.1808.
  200. Popp A, Zysset P, Lippuner K. Rebound-associated vertebral fractures after discontinuation of denosumab—from clinic and biomechanics. Osteoporosis International. 2015;27(5):1917-1921. doi:10.1007/s00198-015-3458-6.
  201. Tsourdi E, Langdahl B, Cohen-Solal M, Aubry-Rozier B, Eriksen EF, Guanabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Zillikens MC. Discontinuation of denosumab therapy for osteoporosis: a systematic review and position statement by ECTS. Bone. 2017;105:11–17.
  202. Tsourdi Elena, Bente Langdahl, Martine Cohen-Solal, Bérengere Aubry-Rozier, Erik Fink Eriksen, Nuria Guañabens, Barbara Obermayer-Pietsch, Stuart H Ralston, Richard Eastell, M Carola Zillikens.Discontinuation of Denosumab therapy for osteoporosis: A systematic review and position statement by ECTS Review. Bone, 2017 Dec;105:11-17.doi: 10.1016/j.bone.2017.08.003. Epub 2017 Aug 5.
  203. Tsourdi E, Zillikens MC, Meier C, Body JJ, Rodriguez EG, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Guañabens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B. Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. 2020 Oct 26:dgaa756. doi: 10.1210/clinem/dgaa756. Online ahead of print.PMID: 33103722
  204. Koldkjær Sølling A, Harsløf T, Kaal A, Rejnmark L, Langdahl B. Hypercalcemia after discontinuation of long-term denosumab treatment. Osteoporosis International. 2016. doi:10.1007/s00198-016-3535-5
  205. Leder BZ, Tsai JN, Uihlein AV, Wallace PM, Lee H, Neer RM, Burnett-Bowie SAM (2015) Denosumab and teriparatide transitions in postmenopausal osteoporosis (the DATA-Switch study): Extension of a randomised controlled trial. Lancet 386(9999):1147- 1155
  206. Ebina K, Hashimoto J, Kashii M, Hirao M, Kaneshiro S, Noguchi T, Tsukamoto Y, Yoshikawa H. The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis. J Bone Miner Metab. 2017 Jan;35(1):91- 98. doi: 10.1007/s00774-015-0731-x
  207. Rittmaster RS, Bolognese M, Ettinger MP, Hanley DA, Hodsman AB, Kendler DL, Rosen CJ. Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate. J Clin Endocrinol Metab. 2000 Jun;85(6):2129-34. doi: 10.1210/jcem.85.6.6614
  208. Diez-Perez A, Adachi JD, Agnusdei D, Bilezikian JP, Compston JE, Cummings SR, Eastell R, Eriksen EF, Gonzales-Macies J, Liberman UA, Wahl DA, Seeman E, Kanis JA, Cooper C.: Treatment failure in osteoporosis. Osteoporosis Int. 2012;(23):2769-2774
  209. Gaál J, Bender T, Varga J et al. Overcoming resistance to bisphosphonates through the administration of alfacalcidol: results of a 1-year, open follow-up study. Rheumatol Int. 2009;30(1):25-31. doi:10.1007/s00296-009-0892-9
  210. Harris ST, Watts NB, Genant HK et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA. 1999; 282:1344–1352.
  211. Reginster J, Minne H, Sorensen O et al. Randomized Trial of the Effects of Risedronate on Vertebral Fractures in Women with Established Postmenopausal Osteoporosis. Osteoporosis International. 2000;11(1):83-91. doi:10.1007/s001980050010.
  212. Meunier P, Roux C, Seeman E et al. The Effects of Strontium Ranelate on the Risk of Vertebral Fracture in Women With Postmenopausal Osteoporosis. N Engl J Med. 2004 Jan 29;350(5):459-68 DOI: 10.1056/NEJMoa022436
  213. British Orthopaedic Association and British Geriatrics Society. The care of patients with fragility fracture. 2007:15-50.
  214. Griffiths R, Alper J, Beckingsale A et al. Management of proximal femoral fractures 2011. Anaesthesia. 2011;67(1):85-98. doi:10.1111/j.1365-2044.2011.06957.x.
  215. Загородний Н.В., Голухов Г.Н., Волна А.А. и др. Диагностика и лечение переломов проксимального отдела бедра у лиц пожилого и старческого возраста. Метод. Рекомендации. Москва, РУДН, 2012.
  216. Roche J. Effect of comorbidities and postoperative complications on mortality after hip fracture in elderly people: prospective observational cohort study. BMJ. 2005;331(7529):1374-0. doi:10.1136/bmj.38643.663843.55.
  217. Kates S, Mendelson D, Friedman S. Co-managed care for fragility hip fractures (Rochester model). Osteoporosis International. 2010;21(S4):621-625. doi:10.1007/s00198-010-1417-9.
  218. Silverman SL, Kupperman ES, Bukata SV, Members of IOF Fracture Working Group Fracture healing: a consensus report from the International Osteoporosis Foundation Fracture Working Group Osteoporos Int (2016) 27:2197–2206 DOI 10.1007/s00198-016- 3513-y
  219. Oliver D, Connelly J, Victor C et al. Strategies to prevent falls and fractures in hospitals and care homes and effect of cognitive impairment: systematic review and meta- analyses. BMJ. 2007;334(7584):82-82. doi:10.1136/bmj.39049.706493.55
  220. Schmidt K, Hübscher M, Vogt L, et al. Influence of spinal orthosis on gait and physical functioning in women with postmenopausal osteoporosis// Der Orthopäde. — 2012. — Vol. 41. — No 3. — Р. 200–205
  221. Pfeifer M, Begerow B, Minne HW. Effects of a new spinal orthosis on posture, trunk strength, and quality of life in women with postmenopausal osteoporosis: a randomized trial. Am J Phys Med Rehabil. 2004; 83:177–186.
  222. Yuan Zhe Jin, Jae Hyup Lee Effect of Brace to Osteoporotic Vertebral Fracture: A Meta- Analysis//J Korean Med Sci 2016; 31: 1641-1649.
  223. Valentin GH, Pedersen LN, Maribo T. Wearing an active spinal orthosis improves back extensor strength in women with osteoporotic vertebral fractures // Prosthetics and orthotics international. — 2014. — Vol. 38. — No 3. — Р. 232–238
  224. Matussek J, Boluki D, Füssel S, Grifka. Orthotic methods for osteoporosis and osteoporotic vertebral fracture. J. Orthopade. 2010 Apr;39(4):387-96. [Article in German] doi: 10.1007/s00132-010-1596-2.
  225. Shariatzadeh H, Modaghegh BS, MD, Mirzaei A. The Effect of Dynamic Hyperextension Brace on Osteoporosis and Hyperkyphosis Reduction in Postmenopausal Osteoporotic Women. Arch Bone Jt Surg. 2017 May; 5(3): 181–185
  226. Snow-Harter C, Bouxsein ML, Lewis BT, Carter DR, Marcus R. Effects of resistance and endurance exercise on bone mineral status of young women: a randomized exercise intervention trial. J Bone Miner Res. 1992; 7: 761-769
  227. Vainionpää A, Korpelainen R, Leppäluoto J, Jämsä T. Effects of high-impact exercise on bone mineral density: a randomized controlled trial in premenopausal women. Osteoporos Int. 2005;16(2):191-7
  228. Yu HS, Kim JJ, Kim HW, Lewis MP, Wall I. Impact of mechanical stretch on the cell behaviors of bone and surrounding tissues. J Tissue Eng. 2016;7:2041731415618342. doi: 10.1177/2041731415618342
  229. Kelley G, Kelley K, Tran Z. Exercise and Lumbar Spine Bone Mineral Density in Postmenopausal Women: A Meta-Analysis of Individual Patient Data. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences. 2002;57(9):M599- M604. doi:10.1093/gerona/57.9.m599.
  230. Michael Y, Whitlock E, Lin J, Fu R, O"Connor E, Gold R. Primary Care–Relevant Interventions to Prevent Falling in Older Adults: A Systematic Evidence Review for the U.S. Preventive Services Task Force. Annals of Internal Medicine. 2010;153(12):815. doi:10.7326/0003-4819-153-12-201012210-00008.
  231. Howe TE, Shea B, Dawson LJ, Downie F, Murray A, Ross C, Harbour RT, Caldwell LM, Creed G (2011) Exercise for preventing and treating osteoporosis in postmenopausal women. Cochrane Database Syst Rev. 2011;(7):CD000333. doi: 10.1002/14651858.CD000333.pub2.
  232. Sherrington C, Whitney J, Lord S, Herbert R, Cumming R, Close J. Effective Exercise for the Prevention of Falls: A Systematic Review and Meta-Analysis. Journal of the American Geriatrics Society. 2008;56(12):2234-2243. doi:10.1111/j.1532- 5415.2008.02014.x.
  233. Howe TE, Rochester L, Neil F, Skelton DA, Ballinger C (2011) Exercise for improving balance in older people. Cochrane Database Syst Rev. 2011 Nov 9;(11):CD004963. doi: 10.1002/14651858.CD004963.pub3.
  234. Li W, Chen Y, Yang R, Tsauo J. Effects of exercise programmes on quality of life in osteoporotic and osteopenic postmenopausal women: a systematic review and meta- analysis. Clinical Rehabilitation. 2009;23(10):888-896. doi:10.1177/0269215509339002.
  235. Smith É, Carroll Á. Bone mineral density in adults disabled through acquired neurological conditions: a review. J Clin Densitom. 2011;14(2):85-94. doi: 10.1016/j.jocd.2010.12.002
  236. Dawson-Hughes B, Mithal A, Bonjour J et al. IOF position statement: vitamin D recommendations for older adults. Osteoporosis International. 2010;21(7):1151-1154. doi:10.1007/s00198-010-1285-3
  237. The DIPART Group. Patient level pooled analysis of 68500 patients from seven major vitamin D fracture prevention in US and Europe. BMJ. 2010;340:b5463
  238. Tripkovic L, Lambert H, Hart K, Smith CP, Bucca G, Penson S, Chope G, Hyppönen E, Berry J, Vieth R, Lanham-New S. Comparison of vitamin D2 and vitamin D3 supplementation in raising serum 25-hydroxyvitamin D status: a systematic review and meta-analysis. Am J Clin Nutr. 2012 Jun;95(6):1357-64. doi: 10.3945/ajcn.111.031070. Epub 2012 May 2. PMID: 22552031; PMCID: PMC3349454.
  239. Hassan AB, Hozayen RF, Alotaibi RA, Tayem YI. Therapeutic and maintenance regimens of vitamin D3 supplementation in healthy adults: A systematic review. Cell Mol Biol (Noisy-le-grand). 2018 Nov 30;64(14):8-14. PMID: 30511630.
  240. Kearns MD, Alvarez JA, Tangpricha V. Large, single-dose, oral vitamin D supplementation in adult populations: a systematic review. Endocr Pract. 2014 Apr;20(4):341-51. doi: 10.4158/EP13265.RA. PMID: 24246341; PMCID: PMC4128480.
  241. Tabatabaeizadeh SA, Avan A, Bahrami A, Khodashenas E, Esmaeili H, Ferns GA, Abdizadeh MF, Ghayour-Mobarhan M. High Dose Supplementation of Vitamin D Affects Measures of Systemic Inflammation: Reductions in High Sensitivity C-Reactive Protein Level and Neutrophil to Lymphocyte Ratio (NLR) Distribution. J Cell Biochem. 2017 Dec;118(12):4317-4322. doi: 10.1002/jcb.26084. Epub 2017 Jun 9. PMID: 28425575.
  242. Esfandiari A, Pourghassem Gargari B, Noshad H, Sarbakhsh P, Mobasseri M, Barzegari M, Arzhang P. The effects of vitamin D3 supplementation on some metabolic and inflammatory markers in diabetic nephropathy patients with marginal status of vitamin D: A randomized double blind placebo controlled clinical trial. Diabetes Metab Syndr. 2019 Jan-Feb;13(1):278-283. doi: 10.1016/j.dsx.2018.09.013. Epub 2018 Sep 12. PMID: 30641712.
  243. Dalle Carbonare L, Valenti MT, Del Forno F, Piacentini G, Pietrobelli A. Vitamin D Daily versus Monthly Administration: Bone Turnover and Adipose Tissue Influences. Nutrients. 2018 Dec 6;10(12):1934. doi: 10.3390/nu10121934. PMID: 30563215; PMCID: PMC6315364.
  244. Venugopal Y, Hatta SFWM, Musa N, Rahman SA, Ratnasingam J, Paramasivam SS, Lim LL, Ibrahim L, Choong K, Tan AT, Chinna K, Chan SP, Vethakkan SR. Maintenance vitamin D3 dosage requirements in Chinese women with post menopausal osteoporosis living in the tropics. Asia Pac J Clin Nutr. 2017 May;26(3):412-420. doi: 10.6133/apjcn.042016.10. PMID: 28429905.
  245. Пигарова Е.А., Рожинская Л.Я., Белая Ж.Е., Дзеранова Л.К., Каронова Т.Л., Ильин А.В., Мельниченко Г.А., Дедов И.И. Клинические рекомендации Российской Ассоциации Эндокринологов по диагностике, лечению и профилактике дефицита витамина D у взрослых. Проблемы эндокринологии. 2016. Т. 62. № 4. С. 60-84
  246. Heaney RP, Davies KM, Chen TC, Holick MF, Barger-Lux MJ: Human serum 25- hydroxychole-calciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr. 2003;77(1):204-10
  247. Broe K, Chen T, Weinberg J, Bischoff-Ferrari H, Holick M, Kiel D. A Higher Dose of Vitamin D Reduces the Risk of Falls in Nursing Home Residents: A Randomized, Multiple-Dose Study. Journal of the American Geriatrics Society. 2007;55(2):234-239. doi:10.1111/j.1532-5415.2007.01048.x.
  248. Institute of Medicine, Food and Nutrition Board. Dietary Reference Intakes for Calcium and Vitamin D. Washington, DC: National Academy Press, 2010
  249. Химический состав пищевых продуктов, используемых в Российской Федерации доступен по ссылке: http://web.ion.ru. Ссылка активна на 05.05.2016
  250. Boonen S, Bischoff-Ferrari H, Cooper C et al. Addressing the Musculoskeletal Components of Fracture Risk with Calcium and Vitamin D: A Review of the Evidence. Calcified Tissue International. 2006;78(5):257-270. doi:10.1007/s00223-005-0009-8.
  251. Tang BM., Eslick CD., Nowson C., et al. Use of calcium or calcium in combination with vitamin D supplementation to prevent fractures and bone loss in people aged 50 years and older; a meta-analysis. Lancet. 2007; 370:657-66.
  252. Richy F, Dukas L, Schacht E. Differential Effects of D-Hormone Analogs and Native Vitamin D on the Risk of Falls: A Comparative Meta-Analysis. Calcified Tissue International. 2008;82(2):102-107. doi:10.1007/s00223-008-9102-0.
  253. Del Valle E, Negri AL, Fradinger E, Canalis M, Bevione P, Curcelegui M, Bravo M, Puddu M, Marini A, Ryba J, Peri P, Rosa Diez G, Sintado L, Gottlieb E.Weekly high- dose ergocalciferol to correct vitamin D deficiency/insufficiency in hemodialysis patients: A pilot trial. Hemodial Int. 2014. doi: 10.1111/hdi.12209
  254. Mager DR, Jackson ST, Hoffmann MR, Jindal K, Senior PA."Vitamin D supplementation and bone health in adults with diabetic nephropathy: the protocol for a randomized controlled trial". BMC Endocr Disord. 2014;14:66. doi: 10.1186/1472-6823- 14-66
  255. Baber R, Panay N, Fenton A. 2016 IMS Recommendations on women’s midlife health and menopause hormone therapy. Climacteric. 2016;19(2):109-150. doi:10.3109/13697137.2015.1129166.
  256. Rossouw JE, Anderson GL, Prentice RL, et al. Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principle results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321-333.
  257. Ettinger B, Ensrud K, Wallace R et al. Effects of Ultralow-Dose Transdermal Estradiol on Bone Mineral Density: A Randomized Clinical Trial. Obstetrics & Gynecology. 2004;104(3):443-451. doi:10.1097/01.aog.0000137833.43248.79.
  258. T.J. de Villiers, J.E. Hall, J.V. Pinkerton, S. Cerdas Perez, M. Rees, C. Yang, D.D. Pierroz Revised global Consensus Statement on Menopausal Hormone Therapy. J. Climacteric 2016 19:4; 313-315
  259. McLellan A, Reid D, Forbes K, et al. Effectiveness of strategies for the secondary prevention of osteoporotic fractures in Scotland (CEPS 99/03): NHS Quality Improvement Scotland. 2004.
  260. Akesson K., Marsh D., Mitchell P.J. et al. Capture the Fracture: a Best Practice Framework and global campaign to break the fragility fracture cycle. Osteoporos Int 2013; 24 (8): 2135-2152.
  261. Hagino H., Sawaguchi T., Endo N., et al. The risk of a second hip fracture in patients after their first hip fracture. Calcif Tissue Int 2012; 90: 14-21.
  262. Dell R. Fracture prevention in Kaiser Permanente Southern California. Osteoporos Int. 2011; 22 Suppl 3: 457-60.
  263. Nakayama A., Major G., Holliday E., Attia J., Bogduk N. Evidence of effectiveness of a fracture liaison service to reduce the re-fracture rate. Osteoporos Int. 2016; 27(3): 873- 9.
  264. Marsh D., Akesson K., Beaton D. E. et al. Coordinator-based systems for secondary prevention in fragility fracture patients. Osteoporos Int. 2011; 22: 2051-2065.
  265. Ganda K., Mitchell P.J., Seibel M.J. Chapter 3 - Models of Secondary Fracture Prevention: Systematic Review and Metaanalysis of Outcomes. Secondary Fracture Prevention. An International Perspective. 2019. P. 33-62
  266. Ganda K, Puech M, Chen JS, Speerin R, Bleasel J, Center JR, et al. Models of care for the secondary prevention of osteoporotic fractures: a systematic review and meta- analysis. OsteoporosInt 2013;24(2):393–406.
  267. Huntjens K.M., van Geel T.A., van den Bergh J.P., et al. Fracture liaison service: impact on subsequent nonvertebral fracture incidence and mortality. J Bone Joint Surg Am. 2014; 96(4): e29.
  268. Hawley S., Javaid M.K., Prieto-Alhambra D., et al. Clinical effectiveness of orthogeriatric and fracture liaison service models of care for hip fracture patients: population-based longitudinal study. Age Ageing. 2016; 45(2): 236-42.
  269. Majumdar S. R., Lier D. A., Rowe B. H. et al. Cost-effectiveness of a multifaceted intervention to improve quality of osteoporosis care after wrist fracture. Osteoporos Int. 2011; 22 (6): 1799-1808.
  270. McLellan A. R., Wolowacz S. E., Zimovetz E. A. et al. Fracture liaison services for the evaluation and management of patients with osteoporotic fracture: a cost-effectiveness evaluation based on data collected over 8 years of service provision. Osteoporos Int. 2011; 22: 2083-2098.
  271. Reginster JY, Seeman E, De Vernejoul MC et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study. J Clin Endocrinol Metab. 2005; 90:2816–2822
  272. Thompson K. Cytosolic Entry of Bisphosphonate Drugs Requires Acidification of Vesicles after Fluid-Phase Endocytosis. Molecular Pharmacology. 2006;69(5):1624-1632. doi:10.1124/mol.105.020776
  273. Dunford J, Rogers M, Ebetino F, Phipps R, Coxon F. Inhibition of Protein Prenylation by Bisphosphonates Causes Sustained Activation of Rac, Cdc42, and Rho GTPases. J Bone Miner Res. 2006;21(5):684-694. doi:10.1359/jbmr.060118
  274. U.S. Food and Drug Administration. Reclast (zoledronic acid): Drug Safety Communication - New Contraindication and Updated Warning on Kidney Impairment. Posted 09/01/2011. Доступно по http://www.fda.gov/Safety/MedWatch/SafetyInformation/ SafetyAlertsforHumanMedicalProducts/ucm270464.htm. Ссылка активна на 12.05.2019
  275. Khosla S, Burr D, Cauley J et al. Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research. J Bone Miner Res. 2007;22(10):1479-1491. doi:10.1359/jbmr.0707onj.
  276. Marie P. Signaling Pathways Affecting Skeletal Health. Current Osteoporosis Reports. 2012;10(3):190-198. doi:10.1007/s11914-012-0109-0.
  277. Tashjian AChabner B. Commentary on Clinical Safety of Recombinant Human Parathyroid Hormone 1-34 in the Treatment of Osteoporosis in Men and Postmenopausal Women. J Bone Miner Res. 2002;17(7):1151-1161. doi:10.1359/jbmr.2002.17.7.1151.
  278. Vahle J, Sato M, Long G et al. Skeletal Changes in Rats Given Daily Subcutaneous Injections of Recombinant Human Parathyroid Hormone (1-34) for 2 Years and Relevance to Human Safety. Toxicologic Pathology. 2002;30(3):312-321. doi:10.1080/01926230252929882.
  279. Miller P, Schwartz E, Chen P, Misurski D, Krege J. Teriparatide in postmenopausal women with osteoporosis and mild or moderate renal impairment. Osteoporosis International. 2006;18(1):59-68. doi:10.1007/s00198-006-0189-8.
  280. Nielsen S, Slosman D, Sørensen O et al. Influence of Strontium on Bone Mineral Density and Bone Mineral Content Measurements by Dual X-Ray Absorptiometry. Journal of Clinical Densitometry. 1999;2(4):371-379. doi:10.1016/s1094-6950(06)60402-2.
  281. Recker R, Marin F, Ish-Shalom S et al. Comparative Effects of Teriparatide and Strontium Ranelate on Bone Biopsies and Biochemical Markers of Bone Turnover in Postmenopausal Women With Osteoporosis*. Journal of Bone and Mineral Research. 2009;24(8):1358-1368. doi:10.1359/jbmr.090315.

Для продолжения работы требуется Регистрация
На предыдущую страницу

Предыдущая страница

Следующая страница

На следующую страницу
Список литературы
На предыдущую главу Предыдущая глава
оглавление
Следующая глава На следующую главу

Оглавление

Данный блок поддерживает скрол*